concentrations during the postprandialperiod. A long-acting once-weekly for-mulation of exenatide (exenatide QW)has been developed. Weekly administra-tion of 2 mg exenatide QW results in ther-apeutic plasma exenatide concentrationswithin 2 weeks and steady-state plasmaexenatide concentrations within the ther-apeutic target range 6–7 weeks after ini-tiation of therapy (17,18). ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● From the1Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; the2Department of Medicine, Banting and Best Diabetes Centre, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario,Canada; 3Amylin Pharmaceuticals, San Diego, California; and4Lilly Research, Eli Lilly and Company, Indianapolis, Indiana.